Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Ane Ogbe; Matthew Pace; Mustapha Bittaye; Timothy Tipoe; Sandra Adele; Jasmini Alagaratnam; Parvinder K. Aley; M. Azim Ansari; Anna Bara; Samantha Broadhead; Anthony Brown; Helen Brown; Federica Cappuccini; Paola Cinardo; Wanwisa Dejnirattisai; Katie J. Ewer; Henry Fok; Pedro M. Folegatti; Jamie Fowler; Leila Godfrey; Anna L. Goodman; Bethany Jackson; Daniel Jenkin; Mathew Jones; Stephanie Longet; Rebecca A. Makinson; Natalie G. Marchevsky; Moncy Mathew; Andrea Mazzella; Yama F. Mujadidi; Lucia Parolini; Claire Petersen; Emma Plested; Katrina M. Pollock; Thurkka Rajeswaran; Maheshi N. Ramasamy; Sarah Rhead; Hannah Robinson; Nicola Robinson; Helen Sanders; Sonia Serrano; Tom Tipton; Anele Waters; Panagiota Zacharopoulou; Eleanor Barnes; Susanna Dunachie; Philip Goulder; Paul Klenerman; Gavin R. Screaton; Alan Winston; Adrian V.S. Hill; Sarah C. Gilbert; Miles Carroll; Andrew J. Pollard; Sarah Fidler; Julie Fox; Teresa Lambe; John Frater

doi:10.1172/jci.insight.157031

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Ane Ogbe^*, Matthew Pace, Mustapha Bittaye, Timothy Tipoe, Sandra Adele, Jasmini Alagaratnam, Parvinder K. Aley, M. Azim Ansari, Anna Bara, Samantha Broadhead, Anthony Brown, Helen Brown, Federica Cappuccini, Paola Cinardo, Wanwisa Dejnirattisai, Katie J. Ewer, Henry Fok, Pedro M. Folegatti, Jamie Fowler, Leila GodfreyAnna L. Goodman, Bethany Jackson, Daniel Jenkin, Mathew Jones, Stephanie Longet, Rebecca A. Makinson, Natalie G. Marchevsky, Moncy Mathew, Andrea Mazzella, Yama F. Mujadidi, Lucia Parolini, Claire Petersen, Emma Plested, Katrina M. Pollock, Thurkka Rajeswaran, Maheshi N. Ramasamy, Sarah Rhead, Hannah Robinson, Nicola Robinson, Helen Sanders, Sonia Serrano, Tom Tipton, Anele Waters, Panagiota Zacharopoulou, Eleanor Barnes, Susanna Dunachie, Philip Goulder, Paul Klenerman, Gavin R. Screaton, Alan Winston, Adrian V.S. Hill, Sarah C. Gilbert, Miles Carroll, Andrew J. Pollard, Sarah Fidler, Julie Fox, Teresa Lambe, John Frater

^*Corresponding author for this work

Research & Development Institute Divisional Office

Research output: Contribution to journal › Article › peer-review

34 Citations (Scopus)

6 Downloads (Pure)

Abstract

Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4(+) T cells > 350 cells/mu L) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-gamma ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.

Original language	English
Article number	e157031
Number of pages	19
Journal	JCI Insight
Volume	7
Issue number	7
DOIs	https://doi.org/10.1172/jci.insight.157031
Publication status	Published - 8 Apr 2022

Bibliographical note

Publisher Copyright:
© 2022, Ogbe et al.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1172/jci.insight.157031

Cite this

Ogbe, A., Pace, M., Bittaye, M., Tipoe, T., Adele, S., Alagaratnam, J., Aley, P. K., Ansari, M. A., Bara, A., Broadhead, S., Brown, A., Brown, H., Cappuccini, F., Cinardo, P., Dejnirattisai, W., Ewer, K. J., Fok, H., Folegatti, P. M., Fowler, J., ... Frater, J. (2022). Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 7(7), Article e157031. https://doi.org/10.1172/jci.insight.157031

@article{2561da15f5b24d9db24ec98ab15f4b9a,

title = "Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV",

abstract = "Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4(+) T cells > 350 cells/mu L) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-gamma ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.",

author = "Ane Ogbe and Matthew Pace and Mustapha Bittaye and Timothy Tipoe and Sandra Adele and Jasmini Alagaratnam and Aley, {Parvinder K.} and Ansari, {M. Azim} and Anna Bara and Samantha Broadhead and Anthony Brown and Helen Brown and Federica Cappuccini and Paola Cinardo and Wanwisa Dejnirattisai and Ewer, {Katie J.} and Henry Fok and Folegatti, {Pedro M.} and Jamie Fowler and Leila Godfrey and Goodman, {Anna L.} and Bethany Jackson and Daniel Jenkin and Mathew Jones and Stephanie Longet and Makinson, {Rebecca A.} and Marchevsky, {Natalie G.} and Moncy Mathew and Andrea Mazzella and Mujadidi, {Yama F.} and Lucia Parolini and Claire Petersen and Emma Plested and Pollock, {Katrina M.} and Thurkka Rajeswaran and Ramasamy, {Maheshi N.} and Sarah Rhead and Hannah Robinson and Nicola Robinson and Helen Sanders and Sonia Serrano and Tom Tipton and Anele Waters and Panagiota Zacharopoulou and Eleanor Barnes and Susanna Dunachie and Philip Goulder and Paul Klenerman and Screaton, {Gavin R.} and Alan Winston and Hill, {Adrian V.S.} and Gilbert, {Sarah C.} and Miles Carroll and Pollard, {Andrew J.} and Sarah Fidler and Julie Fox and Teresa Lambe and John Frater",

note = "Publisher Copyright: {\textcopyright} 2022, Ogbe et al.",

year = "2022",

month = apr,

day = "8",

doi = "10.1172/jci.insight.157031",

language = "English",

volume = "7",

journal = "JCI Insight",

issn = "2379-3708",

publisher = "American Society for Clinical Investigation",

number = "7",

}

Ogbe, A, Pace, M, Bittaye, M, Tipoe, T, Adele, S, Alagaratnam, J, Aley, PK, Ansari, MA, Bara, A, Broadhead, S, Brown, A, Brown, H, Cappuccini, F, Cinardo, P, Dejnirattisai, W, Ewer, KJ, Fok, H, Folegatti, PM, Fowler, J, Godfrey, L, Goodman, AL, Jackson, B, Jenkin, D, Jones, M, Longet, S, Makinson, RA, Marchevsky, NG, Mathew, M, Mazzella, A, Mujadidi, YF, Parolini, L, Petersen, C, Plested, E, Pollock, KM, Rajeswaran, T, Ramasamy, MN, Rhead, S, Robinson, H, Robinson, N, Sanders, H, Serrano, S, Tipton, T, Waters, A, Zacharopoulou, P, Barnes, E, Dunachie, S, Goulder, P, Klenerman, P, Screaton, GR, Winston, A, Hill, AVS, Gilbert, SC, Carroll, M, Pollard, AJ, Fidler, S, Fox, J, Lambe, T & Frater, J 2022, 'Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV', JCI Insight, vol. 7, no. 7, e157031. https://doi.org/10.1172/jci.insight.157031

TY - JOUR

T1 - Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

AU - Ogbe, Ane

AU - Pace, Matthew

AU - Bittaye, Mustapha

AU - Tipoe, Timothy

AU - Adele, Sandra

AU - Alagaratnam, Jasmini

AU - Aley, Parvinder K.

AU - Ansari, M. Azim

AU - Bara, Anna

AU - Broadhead, Samantha

AU - Brown, Anthony

AU - Brown, Helen

AU - Cappuccini, Federica

AU - Cinardo, Paola

AU - Dejnirattisai, Wanwisa

AU - Ewer, Katie J.

AU - Fok, Henry

AU - Folegatti, Pedro M.

AU - Fowler, Jamie

AU - Godfrey, Leila

AU - Goodman, Anna L.

AU - Jackson, Bethany

AU - Jenkin, Daniel

AU - Jones, Mathew

AU - Longet, Stephanie

AU - Makinson, Rebecca A.

AU - Marchevsky, Natalie G.

AU - Mathew, Moncy

AU - Mazzella, Andrea

AU - Mujadidi, Yama F.

AU - Parolini, Lucia

AU - Petersen, Claire

AU - Plested, Emma

AU - Pollock, Katrina M.

AU - Rajeswaran, Thurkka

AU - Ramasamy, Maheshi N.

AU - Rhead, Sarah

AU - Robinson, Hannah

AU - Robinson, Nicola

AU - Sanders, Helen

AU - Serrano, Sonia

AU - Tipton, Tom

AU - Waters, Anele

AU - Zacharopoulou, Panagiota

AU - Barnes, Eleanor

AU - Dunachie, Susanna

AU - Goulder, Philip

AU - Klenerman, Paul

AU - Screaton, Gavin R.

AU - Winston, Alan

AU - Hill, Adrian V.S.

AU - Gilbert, Sarah C.

AU - Carroll, Miles

AU - Pollard, Andrew J.

AU - Fidler, Sarah

AU - Fox, Julie

AU - Lambe, Teresa

AU - Frater, John

PY - 2022/4/8

Y1 - 2022/4/8

N2 - Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4(+) T cells > 350 cells/mu L) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-gamma ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.

AB - Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4(+) T cells > 350 cells/mu L) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-gamma ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.

UR - http://www.scopus.com/inward/record.url?scp=85128131875&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.157031

DO - 10.1172/jci.insight.157031

M3 - Article

C2 - 35192543

AN - SCOPUS:85128131875

SN - 2379-3708

VL - 7

JO - JCI Insight

JF - JCI Insight

IS - 7

M1 - e157031

ER -

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this